Advanced search

Online first
Expert opinion
Published online: 2024-05-02

open access

View PDF Download PDF file
Supp./Additional Files
Page views 204
Article views/downloads 191
Get Citation

Connect on Social Media

Connect on Social Media

Genetic testing for inherited cardiovascular diseases. A position statement of the Polish Cardiac Society endorsed by Polish Society of Human Genetics and Cardiovascular Patient Communities

Elżbieta K Biernacka1, Tadeusz Osadnik234, Zofia T Bilińska5, Maciej Krawczyński6, Anna Latos-Bieleńska6, Izabela Łaczmańska7, Maria Miszczak-Knecht8, Rafał Płoski9, Joanna K Ponińska10, Aleksander Prejbisz11, Paweł Rubiś12, Aleksandra Rudnicka13, Krzysztof Szczałuba914, Justyna A Szczygieł15, Paweł Własienko1617, Agnieszka Wołczenko18, Agnieszka Zienciuk-Krajka19, Lidia Ziółkowska8, Robert Gil20
DOI: 10.33963/v.phj.100490
Pubmed: 38712785

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Davis CG, Lehrman MA, Russell DW, et al. The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell. 1986; 45(1): 15–24.
    CrossRefPubMed
  2. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990; 62(5): 999–1006.
    CrossRefPubMed
  3. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991; 352(6333): 337–339.
    CrossRefPubMed
  4. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80(5): 795–803.
    CrossRefPubMed
  5. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998; 392(6673): 293–296.
    CrossRefPubMed
  6. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999; 341(23): 1715–1724.
    CrossRefPubMed
  7. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000; 355(9221): 2119–2124.
    CrossRefPubMed
  8. ClinGen: https://clinicalgenome. (05.12.2023).
  9. Crotti L, Brugada P, Calkins H, et al. From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies. Europace. 2023; 25(8).
    CrossRefPubMed
  10. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006; 355(8): 788–798.
    CrossRefPubMed
  11. Schwartz PJ, Crotti L, George AL. Modifier genes for sudden cardiac death. Eur Heart J. 2018; 39(44): 3925–3931.
    CrossRefPubMed
  12. Wilde AAM, Semsarian C, Márquez MF, et al. Document Reviewers, Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022; 24(8): 1307–1367.
    CrossRefPubMed
  13. Isselbacher EM, Preventza O, Hamilton Black J, et al. Peer Review Committee Members. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2022; 146(24): e334–e482.
    CrossRefPubMed
  14. Wilde AAM, Nannenberg E, van der Werf C. Cardiogenetics, 25 years a growing subspecialism. Neth Heart J. 2020; 28(Suppl 1): 39–43.
    CrossRefPubMed
  15. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011; 8(8): 1308–1339.
    CrossRefPubMed
  16. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405–424.
    CrossRefPubMed
  17. Won D, Kim SeH, Kim B, et al. Reanalysis of genomic sequencing results in a clinical laboratory: advantages and limitations. Front Neurol. 2020; 11: 612.
    CrossRefPubMed
  18. Masson E, Zou WB, Génin E, et al. Expanding ACMG variant classification guidelines into a general framework. Hum Genomics. 2022; 16(1): 31.
    CrossRefPubMed
  19. Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37): 3503–3626.
    CrossRefPubMed
  20. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10(9): 531–547.
    CrossRefPubMed
  21. The diagnostic work-up of genetic and inflammatory dilated cardiomyopathy. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/The-diagnostic-work-up-of-genetic-and-inflammatory-dilated-cardiomyopathy (28.04.2024).
  22. Jordan E, Peterson L, Ai T, et al. Evidence-Based assessment of genes in dilated cardiomyopathy. Circulation. 2021; 144(1): 7–19.
    CrossRefPubMed
  23. Musunuru K, Hershberger RE, Day SM, et al. American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2020; 13(4): e000067.
    CrossRefPubMed
  24. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017; 376(1): 61–72.
    CrossRefPubMed
  25. Corrado D, Basso C, Rizzoli G, et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003; 42(11): 1959–1963.
    CrossRefPubMed
  26. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013; 62(14): 1290–1297.
    CrossRefPubMed
  27. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015; 132(5): 441–453.
    CrossRefPubMed
  28. van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2006; 113(13): 1650–1658.
    CrossRefPubMed
  29. Biernacka EK, Borowiec K, Franaszczyk M, et al. Pathogenic variants in plakophilin-2 gene (PKP2) are associated with better survival in arrhythmogenic right ventricular cardiomyopathy. J Appl Genet. 2021; 62(4): 613–620.
    CrossRefPubMed
  30. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015; 8(3): 437–446.
    CrossRefPubMed
  31. James CA, Syrris P, van Tintelen JP, et al. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. Eur Heart J. 2020; 41(14): 1393–1400.
    CrossRefPubMed
  32. de Brouwer R, Bosman LP, Gripenstedt S, et al. Netherlands ACM Registry. Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2022; 19(10): 1659–1665.
    CrossRefPubMed
  33. Protonotarios A, Bariani R, Cappelletto C, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J. 2022; 43(32): 3053–3067.
    CrossRefPubMed
  34. Pelliccia A, Sharma S, Gati S, et al. ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021; 42(1): 17–96.
    CrossRefPubMed
  35. Karabinowska-Małocha A, Dziewięcka E, Szymańska M, et al. Link between fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy. Kardiol Pol. 2023; 81(7-8): 692–699.
    CrossRefPubMed
  36. Keramida K, Lazaros G, Nihoyannopoulos P. Right ventricular involvement in hypertrophic cardiomyopathy: patterns and implications. Hellenic J Cardiol. 2020; 61(1): 3–8.
    CrossRefPubMed
  37. Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018; 2018(3): 36.
    CrossRefPubMed
  38. Suay-Corredera C, Pricolo MR, Herrero-Galán E, et al. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy. J Biol Chem. 2021; 297(1).
    CrossRefPubMed
  39. Walsh R, Buchan R, Wilk A, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J. 2017; 38(46): 3461–3468.
    CrossRefPubMed
  40. Antoniutti G, Caimi-Martinez FG, Álvarez-Rubio J, et al. Genotype-Phenotype correlation in hypertrophic cardiomyopathy: new variant p.Arg652Lys in . Genes (Basel). 2022; 13(2).
    CrossRefPubMed
  41. Keyt LK, Duran JM, Bui QM, et al. Thin filament cardiomyopathies: a review of genetics, disease mechanisms, and emerging therapeutics. Front Cardiovasc Med. 2022; 9.
    CrossRefPubMed
  42. Li Q, Gruner C, Chan RH, et al. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014; 7(4): 416–422.
    CrossRefPubMed
  43. O'Mahony C, Jichi F, Pavlou M, et al. Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014; 35(30): 2010–2020.
    CrossRefPubMed
  44. Topriceanu CC, Pereira AC, Moon JC, et al. Meta-Analysis of penetrance and systematic review on transition to disease in genetic hypertrophic cardiomyopathy. Circulation. 2024; 149(2): 107–123.
    CrossRefPubMed
  45. Rapezzi C, Aimo A, Barison A, et al. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022; 43(45): 4679–4693.
    CrossRefPubMed
  46. Grzybowski J, Podolec P, Holcman K, et al. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: a position statement of the polish cardiac society. Kardiol Pol. 2023; 81(11): 1167–1185.
    CrossRefPubMed
  47. Charron P, Elliott P, Gimeno J, et al. The cardiomyopathy registry of the eurobservational research programme of the european society of cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal. 2018; 39(20): 1784–1793.
    CrossRefPubMed
  48. Brodehl A, Gerull B. Genetic insights into primary restrictive cardiomyopathy. J Clin Med. 2022; 11(8).
    CrossRefPubMed
  49. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993; 88(2): 782–784.
    CrossRefPubMed
  50. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012; 5(4): 868–877.
    CrossRefPubMed
  51. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013; 10(12): 1932–1963.
    CrossRefPubMed
  52. Crotti L, Spazzolini C, Tester DJ, et al. Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. Eur Heart J. 2019; 40(35): 2964–2975.
    CrossRefPubMed
  53. Mazzanti A, Guz D, Trancuccio A, et al. Natural history and risk stratification in Andersen-Tawil syndrome type 1. J Am Coll Cardiol. 2020; 75(15): 1772–1784.
    CrossRefPubMed
  54. Pflaumer A, Wilde AAM, Charafeddine F, et al. 50 years of catecholaminergic polymorphic ventricular tachycardia (CPVT) - time to explore the dark side of the moon. Heart Lung Circ. 2020; 29(4): 520–528.
    CrossRefPubMed
  55. Krahn AD, Behr ER, Hamilton R, et al. Brugada Syndrome. JACC Clin Electrophysiol. 2022; 8(3): 386–405.
    CrossRefPubMed
  56. Probst V, Wilde AAM, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009; 2(6): 552–557.
    CrossRefPubMed
  57. Baranchuk A, Nguyen T, Ryu MH, et al. Brugada phenocopy: new terminology and proposed classification. Ann Noninvasive Electrocardiol. 2012; 17(4): 299–314.
    CrossRefPubMed
  58. Wijeyeratne Y, Tanck M, Mizusawa Y, et al. SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation: Genomic and Precision Medicine. 2020; 13(6): e002911.
    CrossRef
  59. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
    CrossRefPubMed
  60. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014; 63(13): 1300–1308.
    CrossRefPubMed
  61. Giustetto C, Scrocco C, Schimpf R, et al. Usefulness of exercise test in the diagnosis of short QT syndrome. Europace. 2015; 17(4): 628–634.
    CrossRefPubMed
  62. Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J. 2022; 43(15): 1500–1510.
    CrossRefPubMed
  63. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007; 115(4): 442–449.
    CrossRefPubMed
  64. Harrell DT, Ashihara T, Ishikawa T, et al. Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. Int J Cardiol. 2015; 190: 393–402.
    CrossRefPubMed
  65. Mazzanti A, Maragna R, Vacanti G, et al. Hydroquinidine prevents life-threatening arrhythmic events in patients with short qt syndrome. J Am Coll Cardiol. 2017; 70(24): 3010–3015.
    CrossRefPubMed
  66. Poninska JK, Bilinska ZT, Franaszczyk M, et al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. J Transl Med. 2016; 14(1): 115.
    CrossRefPubMed
  67. Takeda N, Komuro I. Genetic basis of hereditary thoracic aortic aneurysms and dissections. J Cardiol. 2019; 74(2): 136–143.
    CrossRefPubMed
  68. Rodrigues Bento J, Meester J, Luyckx I, et al. The genetics and typical traits of thoracic aortic aneurysm and dissection. Annu Rev Genomics Hum Genet. 2022; 23: 223–253.
    CrossRefPubMed
  69. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47(7): 476–485.
    CrossRefPubMed
  70. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005; 37(3): 275–281.
    CrossRefPubMed
  71. Jondeau G, Ropers J, Regalado E, et al. Montalcino Aortic Consortium. International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (montalcino aortic consortium). Circ Cardiovasc Genet. 2016; 9(6): 548–558.
    CrossRefPubMed
  72. Franken R, Groenink M, de Waard V, et al. Genotype impacts survival in Marfan syndrome. Eur Heart J. 2016; 37(43): 3285–3290.
    CrossRefPubMed
  73. Hiratzka LF, Bakris GL, Beckman JA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010; 121(13): e266–e369.
    CrossRefPubMed
  74. Guo DC, Papke CL, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009; 84(5): 617–627.
    CrossRefPubMed
  75. Milewicz DM, Guo DC, Tran-Fadulu V, et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008; 9: 283–302.
    CrossRefPubMed
  76. Dobrowolski P, Kabat M, Kępka C, et al. Atherosclerotic cardiovascular disease burden in patients with familial hypercholesterolemia: interpretation of data on involvement of different vascular beds. Pol Arch Intern Med. 2022; 132(4).
    CrossRefPubMed
  77. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
    CrossRefPubMed
  78. Sturm AC, Knowles JW, Gidding SS, et al. Convened by the Familial Hypercholesterolemia Foundation. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018; 72(6): 662–680.
    CrossRefPubMed
  79. Beheshti SO, Madsen CM, Varbo A, et al. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020; 75(20): 2553–2566.
    CrossRefPubMed
  80. Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023; 44(25): 2277–2291.
    CrossRefPubMed
  81. https://databases.lovd.nl/shared/genes/LDLR (05.12.2023).
  82. Chora JR, Iacocca MA, Tichý L, et al. ClinGen Familial Hypercholesterolemia Expert Panel. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022; 24(2): 293–306.
    CrossRefPubMed
  83. Futema M, Taylor-Beadling A, Williams M, et al. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021; 62.
    CrossRefPubMed
  84. Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020; 38(8): 1443–1456.
    CrossRefPubMed
  85. Januszewicz A, Mulatero P, Dobrowolski P, et al. Cardiac phenotypes in secondary hypertension: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 80(15): 1480–1497.
    CrossRefPubMed
  86. Lipshultz SE, Cochran TR, Briston DA, et al. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol. 2013; 9(6): 817–848.
    CrossRefPubMed
  87. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003; 348(17): 1647–1655.
    CrossRefPubMed
  88. Norrish G, Field E, Mcleod K, et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J. 2019; 40(12): 986–993.
    CrossRefPubMed
  89. Baldo F, Fachin A, Da Re B, et al. New insights on Noonan syndrome's clinical phenotype: a single center retrospective study. BMC Pediatr. 2022; 22(1): 734.
    CrossRefPubMed
  90. Yardeni M, Weisman O, Mandel H, et al. Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). Am J Med Genet A. 2017; 173(9): 2461–2466.
    CrossRefPubMed
  91. Zenker M. Clinical overview on RASopathies. Am J Med Genet C Semin Med Genet. 2022; 190(4): 414–424.
    CrossRefPubMed
  92. Ware SM, Bhatnagar S, Dexheimer PJ, et al. Pediatric Cardiomyopathy Registry Study Group. The genetic architecture of pediatric cardiomyopathy. Am J Hum Genet. 2022; 109(2): 282–298.
    CrossRefPubMed
  93. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020; 142(25): e558–e631.
    CrossRefPubMed
  94. Field E, Norrish G, Acquaah V, et al. Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes. J Med Genet. 2022; 59(8): 768–775.
    CrossRefPubMed
  95. Mussa A, Carli D, Giorgio E, et al. MEK inhibition in a newborn with associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease. Genes (Basel). 2021; 13(1).
    CrossRefPubMed
  96. Pignatelli RH, McMahon CJ, Dreyer WJ, et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation. 2003; 108(21): 2672–2678.
    CrossRefPubMed
  97. Finsterer J, Stöllberger C. Left ventricular noncompaction syndrome: genetic insights and therapeutic perspectives. Curr Cardiol Rep. 2020; 22(9): 84.
    CrossRefPubMed
  98. Piekutowska-Abramczuk D, Paszkowska A, Ciara E, et al. Genetic profile of left ventricular noncompaction cardiomyopathy in children-a single reference center experience. Genes (Basel). 2022; 13(8).
    CrossRefPubMed
  99. Jefferies JL, Wilkinson JD, Sleeper LA, et al. Pediatric Cardiomyopathy Registry Investigators. Cardiomyopathy phenotypes and outcomes for children with left ventricular myocardial noncompaction: results from the pediatric cardiomyopathy registry. J Card Fail. 2015; 21(11): 877–884.
    CrossRefPubMed
  100. Klaassen S, Kühnisch J, Schultze-Berndt A, et al. Left ventricular noncompaction in children: the role of genetics, morphology, and function for outcome. J Cardiovasc Dev Dis. 2022; 9(7).
    CrossRefPubMed
  101. Lipshultz SE, Cochran TR, Briston DA, et al. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol. 2013; 9(6): 817–848.
    CrossRefPubMed
  102. Wilde A, Semsarian C, Márquez M, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022; 19(7): e1–e60.
    CrossRefPubMed
  103. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy: a heart failure society of america practice guideline. J Card Fail. 2018; 24(5): 281–302.
    CrossRefPubMed
  104. Hershberger RE, Givertz MM, Ho CY, et al. ACMG Professional Practice and Guidelines Committee. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018; 20(9): 899–909.
    CrossRefPubMed
  105. DeWitt ES, Chandler SF, Hylind RJ, et al. Phenotypic manifestations of arrhythmogenic cardiomyopathy in children and adolescents. J Am Coll Cardiol. 2019; 74(3): 346–358.
    CrossRefPubMed
  106. Smedsrud MK, Chivulescu M, Forså MI, et al. Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2022; 43(45): 4694–4703.
    CrossRefPubMed
  107. Landstrom A, Kim J, Gelb B, et al. Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the american heart association. Circulation: Genomic and Precision Medicine. 2021; 14(5): e000086.
    CrossRef
  108. Pierpont M, Brueckner M, Chung W, et al. Genetic basis for congenital heart disease: revisited: a scientific statement from the american heart association. Circulation. 2018; 138(21): e653–e711.
    CrossRefPubMed
  109. Richter F, Morton SU, Kim SW, et al. Genomic analyses implicate noncoding de novo variants in congenital heart disease. Nat Genet. 2020; 52(8): 769–777.
    CrossRefPubMed
  110. Blue GM, Kirk EP, Giannoulatou E, et al. Advances in the genetics of congenital heart disease: a clinician's guide. J Am Coll Cardiol. 2017; 69(7): 859–870.
    CrossRefPubMed
  111. Donofrio M, Moon-Grady A, Hornberger L, et al. Diagnosis and treatment of fetal cardiac disease. Circulation. 2014; 129(21): 2183–2242.
    CrossRefPubMed
  112. Moon-Grady AJ, Donofrio MT, Gelehrter S, et al. Guidelines and recommendations for performance of the fetal echocardiogram: an update from the american society of echocardiography. J Am Soc Echocardiogr. 2023; 36(7): 679–723.
    CrossRefPubMed
  113. Sieroszewski P, Haus O, Zimmer M, et al. Recommendations for prenatal diagnostics of the Polish Society of Gynaecologists and Obstetricians and the Polish Society of Human Genetics. Ginekol Pol. 2022; 93(5): 427–437.
    CrossRefPubMed
  114. Yasuhara J, Garg V. Genetics of congenital heart disease: a narrative review of recent advances and clinical implications. Transl Pediatr. 2021; 10(9): 2366–2386.
    CrossRefPubMed
  115. Griffin EL, Nees SN, Morton SU, et al. Evidence-Based assessment of congenital heart disease genes to enable returning results in a genomic study. Circ Genom Precis Med. 2023; 16(2): e003791.
    CrossRefPubMed
  116. Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Obstet Gynecol. 2016; 128(6): e262–e268.
    CrossRefPubMed
  117. van Nisselrooij AEL, Lugthart MA, Clur SA, et al. The prevalence of genetic diagnoses in fetuses with severe congenital heart defects. Genet Med. 2020; 22(7): 1206–1214.
    CrossRefPubMed
  118. Fu F, Li Ru, Yu Q, et al. Application of exome sequencing for prenatal diagnosis of fetal structural anomalies: clinical experience and lessons learned from a cohort of 1618 fetuses. Genome Med. 2022; 14(1): 123.
    CrossRefPubMed
  119. Ison HE, Griffin EL, Parrott A, et al. Genetic counseling for congenital heart disease: practice resource of the National Society of Genetic Counselors. J Genet Couns. 2022; 31(1): 9–33.
    CrossRefPubMed
  120. Fellmann F, El Cv, Charron P, et al. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. European Journal of Human Genetics. 2019; 27(12): 1763–1773.
    CrossRefPubMed
  121. Castelletti S, Gray B, Basso C, et al. Indications and utility of cardiac genetic testing in athletes. Eur J Prev Cardiol. 2022; 29(12): 1582–1591.
    CrossRefPubMed
  122. https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/ (29.12.2023).
  123. James CA, Jongbloed JDH, Hershberger RE, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. Circ Genom Precis Med. 2021; 14(3): e003273.
    CrossRefPubMed
  124. Charron P, Arad M, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010; 31(22): 2715–2726.
    CrossRefPubMed
  125. Monaghan KG, Leach NT, Pekarek D, et al. ACMG Professional Practice and Guidelines Committee. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020; 22(4): 675–680.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Polish Heart Journal (Kardiologia Polska)

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice